Dyne Therapeutics (NASDAQ:DYN) Downgraded by StockNews.com

StockNews.com cut shares of Dyne Therapeutics (NASDAQ:DYN – Get Rating) from a hold rating to a sell rating in a research note released on Friday morning.

Other analysts have also issued research reports about the company. Chardan Capital upped their price objective on Dyne Therapeutics from $17.00 to $20.00 and gave the company a buy rating in a research note on Friday, March 3rd. Guggenheim initiated coverage on Dyne Therapeutics in a research note on Thursday, January 26th. They issued a buy rating and a $33.00 price objective on the stock. Oppenheimer initiated coverage on Dyne Therapeutics in a research note on Tuesday, February 14th. They issued an outperform rating and a $34.00 price objective on the stock. Finally, Raymond James upgraded Dyne Therapeutics from an outperform rating to a strong-buy rating and upped their price objective for the company from $16.00 to $27.00 in a research note on Monday, February 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $25.83.

Dyne Therapeutics Stock Performance

DYN opened at $13.43 on Friday. Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. The firm has a market capitalization of $783.04 million, a PE ratio of -4.15 and a beta of 0.23. The business’s 50-day simple moving average is $10.68 and its 200 day simple moving average is $12.00.

Dyne Therapeutics (NASDAQ:DYN – Get Rating) last released its earnings results on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10. On average, research analysts forecast that Dyne Therapeutics will post -3.23 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Principal Financial Group Inc. raised its position in Dyne Therapeutics by 8.9% during the 1st quarter. Principal Financial Group Inc. now owns 11,619 shares of the company’s stock worth $134,000 after purchasing an additional 950 shares during the last quarter. SG Americas Securities LLC raised its position in Dyne Therapeutics by 14.1% during the 1st quarter. SG Americas Securities LLC now owns 11,183 shares of the company’s stock worth $129,000 after purchasing an additional 1,380 shares during the last quarter. Swiss National Bank raised its position in Dyne Therapeutics by 2.8% during the 4th quarter. Swiss National Bank now owns 62,500 shares of the company’s stock worth $724,000 after purchasing an additional 1,700 shares during the last quarter. Credit Suisse AG raised its position in Dyne Therapeutics by 10.6% during the 2nd quarter. Credit Suisse AG now owns 18,015 shares of the company’s stock worth $124,000 after purchasing an additional 1,729 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Dyne Therapeutics by 4.0% during the 1st quarter. Rhumbline Advisers now owns 51,180 shares of the company’s stock worth $590,000 after purchasing an additional 1,966 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

(Get Rating)

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.